Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
80.98 EUR | -2.62% | -4.90% | -21.36% |
26/06 | Redburn Atlantic Initiates Arkema at Buy | MT |
14/05 | Arkema: collaboration with ProLogium in batteries | CF |
Strengths
- With a P/E ratio at 10.31 for the current year and 9.05 for next year, earnings multiples are highly attractive compared with competitors.
- With regards to fundamentals, the enterprise value to sales ratio is at 0.84 for the current period. Therefore, the company is undervalued.
- The company appears to be poorly valued given its net asset value.
- This company will be of major interest to investors in search of a high dividend stock.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
- For the past year, analysts have significantly revised downwards their profit estimates.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Sector: Commodity Chemicals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-21.36% | 6.5B | - | ||
+0.73% | 99.64B | A- | ||
-11.98% | 58.77B | A- | ||
+75.71% | 48.81B | B | ||
+5.26% | 34.94B | B | ||
+0.61% | 31.15B | A- | ||
+3.47% | 18.62B | B- | ||
+17.33% | 17.44B | C+ | ||
+5.92% | 13.51B | B- | ||
-6.67% | 12.73B | B |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- AKE Stock
- 0IB0 Stock
- Ratings Arkema